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(IPSS) in prostate cancer patients who received image-guided 
volumetric modulated arc therapy (IG-VMAT). 
Materials and Methods: From August 2008 to November 2011, 190 
consecutive prostate cancer patients were treated with IG-VMAT to a 
dose of 76 Gy with daily correction of the target position based on 
cone-beam CT imaging. The IPSS and Common Terminology Criteria 
for Adverse Events (CTCAE) version 4.0 toxicity were prospectively 
scored before VMAT, at the end of VMAT, 1, 3, 6, 12, 18, 24 and 36 
months after VMAT. IPSS resolution was defined as a return to within 1 
point of the score at baseline. Clinical, treatment-related parameters 
were evaluated included patient age, alpha-blocker use, androgen 
deprivation therapy (ADT) use, body mass index, diabetes, 
hypertension, smoking and drinking habits, and prostate volume. 
Dosimetric quality indicators were also examined. 
Results: The median follow-up was 24.2 months (range,11.3-47.6). 
134 (70.5%) patients took ADT medications. At last follow-up, 67 
(35.3%) patients took alpha-blocker medications. The 2-year actuarial 
rate of grade 2 or greater genitourinary toxicity was 2.6%. The median 
(inter-quartile range) IPSS before VMAT, at the end of VMAT, 1, 3 
months after VMAT and at last follow-up were 3(1-7), 9(5-12), 6(2-9), 
3(1-8), and 4(1-7), respectively. The IPSS returned to baseline at a 
median of 3.0 months. The IPSS of 49 patients (25.8%) didn't exceed 
baseline+2 throughout the follow up. In Cox regression analysis, only 
drinking habit was associated with increased IPSS exceed baseline+2 
(95% CI 0.283-0.907, p=0.022). 
Conclusions: In IG-VMAT, IPSS resolved within 3 months substantially, 
and late GU toxicity was very low. Cessation of drinking during 
radiotherapy may be useful for further improvement. 
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Purpose/Objective: Most researchers consider kidney cancer 
radioresistant and in light of this what seems to be the 'common 
knowledge' use of radiation therapy to treat those lesions is not 
effective. An analysis of traditional approach indicate the possibility 
of changing that dogma, aiming to of achieve positive results in the 
implementation of radiosurgical abilities to deliver ablative radiation 
doses by means of radiosurgical system CyberKnife. 
Materials and Methods: Fifty patients with medically inoperable renal 
cell cancer (RCC), (from October 2009 to December 2012) were 
treated with robotic SBRT CyberKnife modalities. Eighteen (18) of 
them were diagnosed with single kidney (RCC). All 18 patients had 
metastases from malignant kidney to contralateral kidney and three of 
them had metastases spread to brain, lung, and pancreas. 
Dose/fractionation schedules varied between 10 to 13 Gy per 
fractionand 3 to 4 sessions on kidney and 15 to 20 Gy, 1 to 3 sessions 
on other metastases depending on target location, and size. Tumor 
volume varied from 5 to 180 cc. Follow-up times for patients who 
remained alive were 6 to 25 months and for those who died 
(2patients) were 14 to17 months. 
Results: All eighteen patients were carefully followed by 
multidisciplinary team, contrasted CT scans, renal scintigraphy, and 
blood work was analyzed. Local controls defined as radiologically 
stable disease or partial/complete response was obtained in all 
eighteen patients with single kidney. A partial response as defined as 
a greater than 50% reductions tumor volume was noted in 12 patients. 
Kidney function remained unaffected after treatment in seventeen 
patients, the Creatinine levels remained normal, but one (slightly 
elevated up to 125 mmol/L). Parameters of the dynamic renal 
scintigraphy not affected by the radiosurgery. Side effects were mild, 
grade 1 in 8 cases. No patient was reported with grade 2 to 4 toxicity. 
No complications of the fiducial placement reported. 
Conclusions: The results show positive effect of treatment. These can 
be evaluated as an alternative to surgery and provide local control 
while maintaining the function of a single kidney. Stereotactic body 
radiationtherapy (SBRT), also known as stereotactic ablative 
radiotherapy (SABR), is emerging as one of the new treatment options 
for renal cell cancer (RCC) mainly in medically inoperable patients 
especially reducing surgical risks in patients with single remaining 
kidney.  
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Purpose/Objective: Dose escalation is known to improve outcomes in 
prostate cancer at the expense of a higher risk of side effects. Focal 
dose escalation, targeting the area most at risk of recurrence, may 
improve outcomes without increasing the burden of toxicity, 
especially as the majority of intra-prostatic recurrence occurs at the 
site of the dominant disease nodule at presentation. Fast dose fall-off 
with new radiotherapy techniques such as Cyberknife and Rapid Arc 
improves our ability to dose paint. 
Materials and Methods: Fifteen patients, who were previously treated 
with IMRT at our institution, and had dominant intra-prostatic disease 
nodules (DPDN) on MRI were selected. Their diagnostic MRI was fused 
with their radiotherapy planning CT and the DPDN was contoured with 
the assistance of an expert radiologist. For RapidArc plans, two PTV 
margins were employed: Cyberknife margins (5mm expansion of the 
prostate, except 3mm posteriorly) and larger margins (prostate + 
8mm/4mm posteriorly) in order to account for intra-fraction motion. 
Trial plans were constructed in order to deliver 36.25 Gy in 5 fractions 
to the PTV (as defined above) with a simultaneous integrated boost 
(SIB) of 47.5 Gy to the DPDN which was planned with no PTV margin. 
Minor relaxation of our usual SBRT dose constraints were allowed to 
facilitate the boost dose, as long as the plan was deemed clinically 
acceptable.  
Results: With 5/3mm margins, RapidArc and Multiplan wereboth able 
to produce SIB plans within constraints in most patients. Mean rectal 
D50% and D20% doses were lower for RapidArc compared with 
Multiplan (p=0.01 and 0.005 respectively) but the constraints were 
exceeded in approximately the same number of occasions. If the PTV 
(8/4mm) margin was increased, over half the tolerances were 
exceeded. 
 
Conclusions: Both RapidArc and Multiplan can produce clinically 
acceptable SIB plans, focally escalating to 47.5 Gy, within standard 
OAR constraints. However, if a margin large enough to account for 
intra-fraction motion is used, the RapidArc plans no longer meet the 
required dose constraints. Focal SIB treatments are feasible if intra-
fraction motion can be tracked and corrected.  
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Purpose/Objective: To evaluate a toxicity and efficacy of carbon ion 
radiotherapy for gynecological melanoma, we conducted a Phase I/II 
clinical trial. 
Materials and Methods: The eligibilitycriteria for enrollment in this 
study were (1) histologically proven malignantmelanoma, (2) a 
localized measurable tumor in gynecological region, (3) atleast a 5 
mm gap between the tumor and radiosensitive organs, including bowel 
and bladder, and (4) a expected prognosis of more than 6 months. 
Tumors were classifiedby TNM classification for malignant melanoma. 
In principle, tumors with PTV margins were irradiated 3.6 GyE per 
fraction up to the total dose of 57.6 GyE in 16 fractions, 4 times a 
week. Acute toxicities were assessed according to NCI-CTCAE ver.4.0 
within 3 months after the treatment. Treatment response was 
assessed at 3 month after treatment completion. Late toxicities were 
assessed according to RTOG/EORTC scoring system. Statistical analysis 
of local control and survival were calculated using the Kaplan-Meier 
method. 
Results: A series of 23 gynecological melanoma patients were treated 
with carbonion radiotherapy between November 2004 and October 
2012. The age ranged from 51 to 80 with a median of 71. The tumor 
 
